June 17, 2025 ― On June 17, the Food and Drug Administration announced a new national priority voucher plan whose aim is to reduce drug review times to one to two months from the current average of 10 to 12 months. Chrissy Buteas, president and chief executive officer of the HealthCare Institute of New Jersey, in a statement June 19, said, “Anything that can shorten a review period without compromising safety and efficacy means patients will benefit from new discoveries even sooner.” Read the full article here.